InspireMD Files Preliminary Prospectus for Stock-and-Warrant Offering Led by Lake Street
NSPR sits 58% above its 52-week low of $0.425 on elevated volume (5.1× avg).
Summary
InspireMD filed the preliminary prospectus for the stock-and-warrant offering it announced the same day, with Lake Street as sole book-runner and pricing still blank. The raise comes with cash at $19.2M, a going-concern warning and a Nasdaq bid-price deficiency to cure by January 13, 2027.
Key Events · Financing and Capital Events · NSPR
-
Stock-and-Warrant Offering Launched
Preliminary prospectus for an offering of common stock (or pre-funded warrants) bundled with Series L common warrants; share count, price and proceeds are left blank pending pricing.
-
Lake Street Sole Book-Runner
Lake Street Capital Markets is sole book-running manager, with a 30-day option to buy up to 15% additional shares and/or pre-funded warrants and common warrants.
-
Cash and Going-Concern Pressure
Cash and equivalents were $19,246,000 at September 30, 2026 against a nine-month net loss of $37,775,000; the 10-K audit report carries a going-concern explanatory paragraph.
-
Nasdaq Bid-Price Deadline
A July 17, 2026 notice puts the company out of compliance with the $1.00 minimum bid rule, with until January 13, 2027 to regain compliance; the stock last closed at $0.80 on November 11, 2026.
Analysis · NSPR · Industrial Applications And Services
InspireMD is following through on the public offering it announced hours earlier, now with the mechanics in writing: shares sold together with Series L warrants, pre-funded warrants for buyers hitting the 4.99%/9.99% ownership caps, a 15% over-allotment option and a 60-day company lock-up. Size and price are still blank, so the dilution cannot be pinned down yet — but the context is unforgiving. Cash stood at $19.2M at September 30 against a nine-month net loss of $37.8M, the company carries a going-concern warning, and it received a Nasdaq minimum-bid notice on July 17, 2026 with a January 13, 2027 cure deadline. The stock last closed at $0.80 on November 11, below the $1.00 listing threshold, so new equity is being raised at a depressed level. The FDA's November 9 approval of CGuard Prime 80 cm for TCAR is the offset — the raise funds the U.S. launch — but existing holders absorb the dilution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NSPR was trading at $0.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.